ECSTASY HAS DRAMATIC EFFECT ON PARKINSON'S SYMPTOMS

Ecstasy is being hailed as the key to better treatments for the Parkinson's
disease, marking a complete turnaround from a few weeks ago when ecstasy was
condemned for causing the disease.

New animal studies have confirmed anecdotal reports that ecstasy can
dramatically curb the uncontrollable arm and leg movements that plague so
many people with Parkinson's. But the finding may be of little immediate
help to sufferers.

The researchers are not calling for patients to be given legal supplies of
ecstasy (MDMA). Instead, they want to look for related drugs with the same
beneficial effects. And patients are being warned against trying MDMA for
themselves. "It's impure, illegal and dangerous," says Robert Meadowcroft,
policy director of Britain's Parkinson's Disease Society.

Others are calling for further animal studies to establish the effective
dose, followed by human trials. "People who are suffering should have the
right to decide carefully for themselves whether or not to take MDMA," says
American drugs policy campaigner Rick Doblin. His organisation, MAPS,
recently won approval from the Food and Drug Administration for a human
trial of ecstasy for treating post-traumatic stress disorder.

Regaining Control

The latest study was prompted by the experiences of a former stuntman, Tim
Lawrence. He made headlines when he claimed in a BBC TV documentary that "E"
enabled him to regain control of his body for hours at a time.

Parkinson's experts at the University of Manchester decided to test
Lawrence's claims. Concerns about the dangers of MDMA ruled out human
trials, says team member Jonathan Brotchie, who now runs Manchester-based
biotech company Motac. So the researchers turned to marmosets with a form of
the disease.

Parkinson's is caused by a loss of the dopamine-producing cells in the
brain. Symptoms include rigidity and a shuffling gait. Since the late 1960s
doctors have treated it with L-dopa, a chemical precursor to dopamine that
can "unfreeze" patients.

The downside is that patients develop uncontrollable movements after taking
L-dopa for a while. Their condition tends to oscillates between flailing
limbs while on the drug and immobility off it.

To mimic Parkinson's, they gave six marmosets a chemical that kills dopamine
neurons. Then, over the next few months, the monkeys had daily doses of
L-dopa until they developed the usual side effect of uncontrolled movements.
At this point the animals were given MDMA.

Dramatic Effects

The effects were dramatic. Normally, monkeys on L-dopa move their arms and
legs around in a repetitive and uncontrolled way virtually all the time. But
in the six hours after a dose of MDMA, these movements happened no more than
15 per cent of the time. MDMA somehow reduces the debilitating side effects
of L-dopa without blocking its beneficial effects.

"The magnitude and quality of the effect took us by surprise," says
Brotchie, whose team's findings were unveiled this week at the conference of
the Society for Neuroscience in Florida. "It was always possible that Tim's
response to ecstasy was unusual."

The researchers suspect the finding reflects MDMA's ability to stimulate the
release of the neurotransmitter serotonin in the brain. That might make up
for a lack of serotonin caused by taking L-dopa for prolonged periods, says
Brotchie. However, there are fears that MDMA can damage serotonin-producing
cells.

And last month the journal Science published a paper claiming that MDMA can
actually cause the type of damage to dopamine cells that can lead to
Parkinson's. But the evidence was far from conclusive.